{"entity":{"id":"nct04521231","kind":"trial","name":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","aka":[],"tldr":"A phase 1/2 trial of Blinatumomab in acute lymphoblastic leukaemia, run by Amgen, active and no longer recruiting.","summary":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL is a phase 1/2 interventional study registered as NCT04521231 by Amgen, with 181 participants enrolled, started 2021-01-04 and due to reach its primary completion in 2027-11-24. Interventions recorded: Blinatumomab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04521231","url":"https://clinicaltrials.gov/study/NCT04521231"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["blinatumomab"],"companies":["amgen","beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04521231","phase":"1/2","setting":"A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL","sponsor":"Amgen","enrolled":181,"outcomes":[]},"route":"/trials/nct04521231/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"},{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}